Cardiovascular disease develops 7 to 10 years later in women than in men and is still the major cause of death in women. The risk of heart disease in women is often underestimated due to the misperception that females are 'protected' against cardiovascular disease. The under-recognition of heart disease and differences in clinical presentation in women lead to less aggressive treatment strategies and a lower representation of women in clinical trials. Furthermore, self-awareness in women and identification of their cardiovascular risk factors needs more attention, which should result in a better prevention of cardiovascular events. In this review we summarise the major issues that are important in the diagnosis and treatment of coronary heart disease in women. (Neth Heart J 2010;18:598-603.)
C ardiovascular disease develops 7 to 10 years later in women than in men and is still the major cause of death in women over the age of 65 years. The risk of heart disease in women is often underestimated due to the misperception that females are 'protected' against cardiovascular disease. Recent data from the National Health and Nutrition Examination Surveys (NHANES) have shown that over the past two decades the prevalence of myocardial infarctions has increased in midlife (35 to 54 years) women, while declining in similarly aged men. 1 In a report from the European Heart Survey on stable angina pectoris it was found that women are less likely to be referred for functional testing for ischaemia and that a lower rate of diagnostic angiograms and interventional procedures are performed compared with men. 2 The underrecognition of heart disease and differences in clinical presentation in women lead to less aggressive treatment strategies and a lower representation of women in clinical trials. Furthermore, self awareness in women and identification of their cardiovascular risk factors needs more attention which should result in a better prevention of cardiovascular events. In this review we summarise the major issues that are important in the diagnosis and treatment of coronary heart disease (CHD) in women.
Epidemiology and role of menopause
It is assumed that exposure to endogenous oestrogens during the fertile period of life delays the manifestation of atherosclerotic disease in women. Before menopause the CHD event rate in women is low and predominantly attributed to smoking. 3 Women with an early menopause (<40 years) have a two-year lower life expectancy compared with women with a normal or late menopause. 4 Data from the Framingham Heart Study suggest that a harmful cardiovascular risk profile may be more cause than consequence of age at menopause. In the Women's Ischemia Syndrome Evaluation (WISE) study it was shown that young women with endogenous oestrogen deficiency have a more than sevenfold increase in coronary artery risk. 5 Oestrogens have a regulating effect on several metabolic factors, such as lipids, inflammatory markers and the coagulant system. They also promote a direct vasodilatory effect through the α and β receptors in the vessel wall. Furthermore, signs of subclinical atherosclerosis, as visualised by intima-media thickness measurements, can already be found in women before menopause, especially when several CHD risk factors are present. 6 Flow-mediated vaso reactivity by brachial artery measurements declines with the time elapsed since menopause. After menopause atherosclerotic plaque composition changes into more vulnerable lesions with inflammatory factors involved.
Gender differences in major CHD risk factors
Menopause transition is associated with a worsening CHD risk profile. 7 Women with clinically manifest CHD are in general older than men, with a higher expression of cardiovascular risk factors. 8, 9 Although women and men share most classic risk factors, the significance and the relative weighting of these factors are different. At younger ages (<50 years) smoking is more deleterious in women than in men, with a larger negative impact of the total number of cigarettes smoked per day. 3, 10 Smoking increases the risk of a first acute myocardial infarction (AMI) relatively more in females than in men. In young premenopausal women smoking causes a downregulation of the oestrogen-dependent vasodilatation of the endothelial wall. 11 Whether smoking reduces age at menopause remains a matter of debate.
Body weight may increase during the first years since menopause and body fat distribution changes from a gynoid to a more android pattern. Central obesity with an increase in visceral fat occurs more frequently after menopause, with a higher presence of comorbid risk factors and components of the metabolic syndrome in women compared with ageing men. 12 With the increasing incidence of obesity there is a parallel increase in the prevalence of type 2 diabetes. Women with diabetes are at greater risk for cardiovascular complications than their male counterparts. In a meta-analysis of 37 prospective cohort studies, the risk of fatal CHD is 50% higher in women with diabetes compared with male diabetics. 13 The reason for this higher mortality is multifactorial and related to a heavier risk factor burden, more involvement of inflammatory factors, smaller vessel size of the coronary arteries and an often less aggressive treatment of diabetes in women.
Systolic blood pressure rises more steeply in ageing women compared with men, and this may be related to the decline in oestrogen levels in menopause transition. [14] [15] [16] After menopause there is an upregulation of the renin-angiotensin system, with an increase in plasma-renin activity. Salt sensitivity and sympathetic activity are also increased in postmenopausal compared with premenopausal women. At older age (>75 years) isolated systolic hypertension is 14% more prevalent in women and an important cause of left ventricular hypertrophy, (diastolic) heart failure and strokes. Moderate or borderline hypertension (<140/90 mmHg) causes more endothelial dysfunction and cardiovascular complications in women than in men. 17 Hypertension often starts in the menopausal transition period and can cause a variety of complaints, such as chest pain, palpitations, headaches and even sensations of hot flashes. 18 These complaints are often attributed to menopause but are less prevalent when elevated blood pressure is adequately treated. 19 It is controversial whether women who have relatively more vasomotor symptoms during menopause transition are at greater risk for CHD. 20 At younger age, the relative risk of hypercholesterolaemia is lower in women compared with men. During menopause, total cholesterol and low-density lipoprotein (LDL) levels rise by 10 and 14% respectively and lipoprotein (a) increases 4 to 8%, whereas high-density lipoprotein (HDL) cholesterol levels remain unchanged. 7, 21 It may therefore be important to (re)evaluate the lipid profile after menopause when borderline premenopausal values were found. Above 65 years of age mean LDL cholesterol is higher in women compared with men. At all ages HDL-cholesterol levels are 0.26 to 0.36 mmol/l higher in women but from the Framingham study it is known that a low HDL cholesterol implicates a higher CHD risk in women than in men. 22 Although women have often been underrepresented in many statin trials in the past, there is currently no doubt that in secondary prevention LDL reduction in women leads to an equally lower CHD mortality as in men. 23 On the other hand, in primary prevention the role of statin therapy in women is still controversial. Caution is needed, however, as women have a lower absolute risk in the age groups that have been studied thus far. A recent large Japanese study showed clear benefits of primary prevention with statins in women with moderately elevated cholesterol levels above the age of 55 years. 24 The age difference in the occurrence of CHD events among men and women was accounted for in the JUPITER trial, where comparable benefits of primary prevention with a statin were found in healthy men ≥50 years and in women ≥60 years with normal LDL levels but elevated hs-CRP levels. 25 Female-specific risk factors Although studies have shown that hormonal dysfunction in premenopausal women is associated with an increased risk of atherosclerosis and CHD events, it is still unclear whether the polycystic ovary syndrome (PCOS) is an independent risk factor for atherosclerosis. 5, 26 PCOS occurs in 8 to 10% of women and is an important cause of infertility. Women with this syndrome are at increased risk for development of the metabolic syndrome and type 2 diabetes mellitus. The difficulty in studying cardiovascular events in women with PCOS is due to the low prevalence of these events in premenopausal women. A greater clustering of CHD risk factors and an adverse CHD event rate was found in postmenopausal participants with PCOS within the WISE study population.
Women with a history of hypertensive diseases in pregnancy are at increased risk for hypertension and premature cardiovascular disease later in life. Especially in women after preeclampsia, defined as hypertension (≥140/90 mmHg) and proteinuria (≥0.3 g/24 h) after 20 weeks of gestation, the risk of future CHD is twice as high compared with women who were normotensive during pregnancy. 28 Women with a placental syndrome in combination with poor foetal growth or intrauterine death are considered to be at greatest risk. 29 Hypertensive disorders are thought to be associated with an abnormal placentation leading to aberrant autonomic control and inappropriate release of vasoactive substances causing endothelial dysfunction in the maternal and foetal circulation. In women with gestational diabetes the relative risk to develop type 2 diabetes is even 7 to 12 times higher compared with women with normoglycaemic pregnancies. 30 The characteristics of pregnancy-related disorders provide a unique opportunity for a better cardiovascular risk assessment and prevention, but have not yet been incorporated in the latest guidelines for CHD prevention in women. 31 
Clinical presentation and noninvasive testing for angina pectoris
The clinical presentation of coronary artery disease and the interpretation of noninvasive diagnostic testing is less reliable in women compared with men, especially in the age group below 55 years when the prevalence of coronary artery disease is still relatively low. [32] [33] [34] Chest pain syndromes are more common in women than in men and are less related to the presence of atherosclerosis in the large epicardial coronary arteries. 8, [35] [36] [37] In addition, many causes of noncardiac chest pain can mimic the discomfort that is associated with myocardial ischaemia. Women who are diagnosed with noncardiac chest pain have a twofold increased risk to develop a CHD event in the next five to seven years and have a four times higher risk for re-hospitalisations and recurrent angiograms in the next 180 days. 38, 39 This implicates that traditional diagnostic methods are not optimal for women and that they should be treated more aggressively for their risk factors.
There are no gender-specific criteria for the interpretation of ECGs, although women have a higher heart rate at rest with a longer QT interval. Nonspecific ECG changes at rest, a lower exercise capacity and a smaller vessel size contribute to the lower sensitivity and specificity of noninvasive testing in women. 33 At younger ages, endogenous oestrogen levels can induce ECG changes mimicking ischaemia. Female-specific normograms have been developed for treadmill exercise testing. A low exercise capacity in symptomatic as well as in asymptomatic women is a strong predictor of five-year mortality. Diagnostic accuracy of exercise testing in women can be further improved by assessment of the angina history, oestrogen status and the presence of major CHD risk factors. 40 Stress echocardiography with exercise or dobutamine can be an important test to evaluate wall motion abnormalities and its clinical value is not different between the two genders. The accuracy of myocardial perfusion imaging scans used to be less in women in the past due to smaller vessel size and breast attenuation, but with more advanced SPECT imaging techniques performed with Technetium sestamibi the predictive value of the scans has improved dramatically. 33 It remains important, however, to include signs of chest pain, electrocardiographic abnormalities and a low functional capacity in the interpretation of the scans. Microvascular dysfunction and diffuse coronary atherosclerosis without obstructive lesions is more prevalent in women than in men and can be better visualised with positron emission tomography (PET) and cardiovascular magnetic resonance (CMR) techniques. 37, 41 The relative low availability of these imaging modalities may be an important factor in the under-recognition of these syndromes in women. Calcium scoring with EBTC or multi-slice CT is a very useful modality to rule out the presence of obstructive CHD, but the (cumulative) radiation exposure makes this technique less suitable in premenopausal women and for follow-up purposes. In women >50 years of age who are at intermediate risk for CHD the absence of coronary calcium has a very high (99%) negative predictive value for obstructive coronary atherosclerosis. In all age groups calcium scores are lower in women than in men. 42 Also, the use of coronary computed tomographic angiography (CCTA) at the emergency department is promising as a highly sensitive diagnostic tool in the early triage of women <65 years who present with symptoms of acute chest pain, but this technique has comparable limitations due to radiation exposure. 37 Acute coronary syndromes in women Many analyses of sex-based differences following acute coronary syndromes (ACS) have revealed conflicting results. At presentation in STEMI, both men and women have comparable symptoms of chest pain, but women tend to have more concomitant vaso-vegetative symptoms that can mask the chest pain, with less extensive ST-T elevations at admission especially at younger ages. 8, 43, 44 In women below 55 years of age unstable angina pectoris and non-STEMI are often misdiagnosed at the emergency department. 45 Women with ACS are generally older with more clustering of risk factors that may contribute to their higher risk of mortality. 8, 9, 46 Gender bias in treatment and gender disparities in vascular flow and structure may further add to this increased mortality. An interesting observation is that women with ACS have less extensive obstruc-tive and more diffuse coronary artery disease compared with men, but the event rate in nonobstructive coronary artery disease seems to be higher in women. 8, 37, 47 In a recent large meta-analysis of 11 randomised ACS trials it was shown that sex-based differences in 30-day mortality among patients with various manifestations of ACS are largely explained by clinical differences at presentation and the severity of angiographically documented disease. 48 Other aspects that may account for differences in outcomes between women and men are related to vascular biological factors such as a smaller atheroma burden and slower progression in women, a smaller vessel size, less collateral flow, lower coronary flow reserve, more vascular stiffness, differences in remodelling, and functional differences of smooth muscle cells in the vessel wall. 35, 37, 47 While in STEMI both genders have equal benefit of early percutaneous coronary interventions (PCI), there is abundant evidence that in non-STEMI the therapeutic strategies should be different between men and women. 47, 49 In the FRISC II and RITA 3 trials, early invasive strategy of patients with unstable angina or non-STEMI ACS was proven to reduce mortality in men, but not in women. A meta-analysis of eight combined non-STEMI trials has confirmed that an early conservative strategy in low-risk (biomarker-negative) women is better than an early invasive strategy, which is in line with the already updated ACC/AHA guidelines on non-STEMI in 2007. 50 Mortality after coronary artery bypass surgery (CABG) is higher in women compared with men and this difference is more pronounced in the younger age groups, after adjustment for risk factors. 51 Many factors influence this gender gap, such as comorbid conditions at older age, smaller vessel size, more urgent procedures in women and the presence of hypertensive heart disease. Furthermore, after PCI women have significantly more bleeding complications, especially when glycoprotein IIb/IIIa inhibitors are used. 52 In a metaanalysis of various large ACS trials, no differences were found in the efficacy and safety of clopidogrel between men and women. 53 Chest pain with 'normal' coronary angiograms At younger ages women more often have ACS with angiographically 'normal' coronary arteries than men. 8, 47 The underlying mechanisms of this so-called coronary microvascular dysfunction are diverse and may be related to endothelial reactivity, low endogenous oestrogen levels, coagulation disorders, abnormal inflammatory reactions and its manifestation can have a substantial variability among individuals. 37 Abnormal cardiac nociception can further attribute to persistent chest pain due to an increased coronary pain perception in women. 54 When symptoms of microvascular dysfunction result in objective signs of ischaemia it is proposed to call this syndrome microvascular angina pectoris. The relationship between microvascular dysfunction and epicardial atherosclerosis is not yet fully understood. The prognosis of this syndrome is less beneficial than initially considered and often leads to recurrent hospitalisations and repeated coronary angiograms. 39, 55 The prognosis is worse in women with various risk factors and these should be treated aggressively to prevent future CHD events.
Conclusion
Cardiovascular disease is the major cause of death in women and is still under-recognised and undertreated. A greater awareness of the differences in presentation of angina pectoris and ACS between men and women, with gender-based interpretation of diagnostic tests, is mandatory for health care professionals to improve therapeutic strategies and outcomes in women. Cardiology guidelines should be more focused on sex-related differences when appropriate. Further, women themselves need to be more aware of their own risk factors and clinical signs of CHD. Many biological differences in atherosclerosis between men and women are not yet clarified and will need further research in the future. ■
